Kedplasma LLC

Form 483 issued March 3, 2026

Inspection
Feb 24 – Mar 3, 2026
Investigator
Elyshia Q. Danaher
Observations
1
Pages
3
FEI number
3014947536

In short: On March 3, 2026, FDA issued a Form 483 with 1 observation to Kedplasma LLC (FEI 3014947536) after an inspection that ran Feb 24 – Mar 3, 2026. The investigator was Elyshia Q. Danaher. Most observations concern biologics CGMP; the most-cited regulation is 21 CFR 606.100 (standard operating procedures).

At a glance

1 of 1 observations on this 483 concern biologics cgmp.

Biologics CGMP1

Most cited: 21 CFR 606.100 (1×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Written standard operating procedures including all steps to be followed in the storage of blood and…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Kedplasma LLC?

FDA listed 1 observation on this Form 483, mostly about biologics CGMP. The most-cited regulation is 21 CFR 606.100 (standard operating procedures). The opening words of each observation are shown on this page.

Who inspected Kedplasma LLC?

Elyshia Q. Danaher is named on this Form 483, for the inspection of Feb 24 – Mar 3, 2026. Each investigator has a profile showing what they cite most.

When was Kedplasma LLC inspected by FDA?

The inspection ran Feb 24 – Mar 3, 2026, and the Form 483 is dated March 3, 2026.

How do I get the full Form 483 for Kedplasma LLC?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free